Symptoms of sexual dysfunction in patients treated for major depressive disorder: A meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale

Journal of Clinical Psychiatry

Volumn 68, Issue 12, 2007, Pages 1860-1866

  Clayton, Anita H ^a   Campbell, Bryan J ^b   Favit, Antonella ^b,f   Yang, Ying ^b   Moonsammy, George ^c,g   Piontek, Catherine M ^d   Amsterdam, Jay D ^e  

^a UNIVERSITY OF VIRGINIA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Somerset Pharmaceuticals   (United States)

^d IneXel Medical Strategy and Communications   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f SHIRE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SELEGILINE;

AROUSAL; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; META ANALYSIS; ORGASM; PRIORITY JOURNAL; SEX DIFFERENTIATION; SEXUAL DYSFUNCTION; SEXUAL SATISFACTION; SYSTEMATIC REVIEW;

EID: 38049009300     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1205     Document Type: Article

References (53)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder [Revision]. Am J Psychiatry 2000;157(suppl 4):1-45
2. Zimmerman M, Posternak M, Friedman M, et al. Which factors influence psychiatrists' selection of antidepressants? Am J Psychiatry 2004;161:1285-1289
3. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-366
4. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-281
5. Montejo AL, Llorca G, Izquierdo JA, et al, for the Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry 2001;62(suppl 3):10-21
6. Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32
7. Ashton AK, Jamerson BD, Weinstein WL, et al. Antidepressant-related adverse effects impacting treatment compliance: results of a patient survey. Curr Ther Res Clin Exp 2005;66:96-106
8. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry 2004;65:959-965
9. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55:1128-1132
10. Sood N, Treglia M, Obenchain RL, et al. Determinants of antidepressant treatment outcome. Am J Manag Care 2000;6:1327-1336
11. Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003;361:653-661
12. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002;159:1869-1875
13. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-214
14. Feiger AD, Rickels K, Rynn MA, et al. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. J Clin Psychiatry 2006;67:1354-1361
15. Amsterdam JD, Bodkin JA. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial. J Clin Psychopharmacol 2006;26:579-586
16. EMSAM [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2006
17. Marwick C. Survey says patients expect little physician help on sex. JAMA 1999;281:2173-2174
18. Nusbaum MR, Hamilton CD. The proactive sexual health history. Am Fam Physician 2002;66:1705-1712
19. Montejo-González AL, Liorca JA, Izquierdo A, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997;23:176-194
20. Bonierbale M, Lançon C, Tignol J. The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin 2003;19:114-124
21. Landén M, Högberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005;66:100-106
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
23. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, 3: efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
25. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
27. Normand ST. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321-359
28. Mooney CZ, Duval RD. Bootstrapping: A Nonparametric Approach to Statistical Inference. Newbury Park, Calif: Sage Publications, Inc; 1993
29. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry 1997;154:1757-1759
30. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006;51:234-242
31. Kennedy SH, Dickens SE, Eisfeld BS, et al. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56:201-208
32. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999;19:67-85
33. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-215
34. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-1048
35. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry 2006;67(suppl 6):33-37
36. McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40
37. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005;66:686-692
38. Meston CM, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:1012-1030
39. Stahl SM, Zhang L, Damatarca C, et al. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. J Clin Psychiatry 2003;64(suppl 14):6-17
40. Tremblay LK, Naranjo CA, Graham SJ, et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005;62:1228-1236
41. Nestler EJ, Carlezon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151-1159
42. Melis MR, Argiolas A. Dopamine and sexual behavior. Neurosci Biobehav Rev 1995;19:19-38
43. Clayton AH. Sexual function and dysfunction in women. Psychiatr Clin North Am 2003;26:673-682
44. Hull EM, Muschamp JW, Sato S. Dopamine and serotonin: influences on male sexual behavior. Physiol Behav 2004;83:291-307
45. Ben Zion IZ, Tessler R, Cohen L, et al. Polymorphisms in the dopamine D4 receptor gene (DRD4) contribute to individual differences in human sexual behavior: desire, arousal and sexual function. Mol Psychiatry 2006;11:782-786
46. Labbate LA, Croft HA, Oleshansky MA. Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation. J Clin Psychiatry 2003;64(suppl 10):11-19
47. Bishop JR, Moline J, Ellingrod VL, et al. Serotonin 2A-1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31:2281-2288
48. Stahl SM. Basic psychopharmacology of antidepressants, pt 1: antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(suppl 4):5-14
49. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl 1983;95:57-80
50. Berry MD, Juorio AV, Paterson IA. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 1994;44:141-161
51. Mawhinney M, Cole D, Azzaro AJ. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues. J Pharm Pharmacol 2003;55:27-34
52. Wecker L, James S, Copeland N, et al. Transdermal selegiline: targeted effects on monoamine oxidases in the brain. Biol Psychiatry 2003;54:1099-1104
53. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology 2005;30:445-460